ClinicalTrials.gg
RecruitingNCT07277387Updated Jun 15, 2026

Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile Neutropenia

An observational study in Febrile Neutropenia, sponsored by Instituto de Investigación Biomédica de Salamanca. Recruiting at 3 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Instituto de Investigación Biomédica de Salamanca · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years and older
Sex
All
01

Study summary

Febrile neutropenia (FN) is a common oncologic emergency in patients with hematologic malignancies, associated with high morbidity and mortality. Early identification of patients at higher risk of complications such as sepsis or septic shock is critical to optimize antimicrobial management.

This study aims to characterize the human and microbial plasma proteome using high-resolution mass spectrometry to identify biomarker combinations ("combitypes") capable of predicting complications in oncohematologic patients with FN.

A cohort of 350 adult patients with high-risk FN and initially uncomplicated clinical presentation will be enrolled across three tertiary hospitals. Plasma samples will be collected at fever onset (before antibiotic initiation) and after 48 hours. Proteomic data will be integrated with clinical information using multivariate and machine learning models to develop a predictive model for complications.

Read the detailed description

This multicenter, prospective, observational study will evaluate whether combined proteomic profiles of host and microbial origin can predict complications in patients with hematologic malignancies presenting with high-risk febrile neutropenia (FN).

FN is defined as an oral temperature ≥38.3 °C once or ≥38.0 °C for ≥1 hour in patients with an absolute neutrophil count (ANC) \<500 cells/mm³ or expected to decrease below that threshold within 48 hours. Despite empirical broad-spectrum antibiotics, up to 50% of these patients develop sepsis, and 10% progress to septic shock.

Current biomarkers such as C-reactive protein (CRP) or procalcitonin (PCT) have limited specificity in this immunocompromised population. This study proposes a novel integrative proteomic approach based on mass spectrometry to simultaneously quantify host and microbial proteins in plasma, identifying molecular patterns associated with poor outcomes.

Plasma samples (10 mL, EDTA) will be obtained at two time points: the first febrile episode (prior to antibiotic administration) and 48 hours later. Proteins will be processed using PreOmics® ENRICHplus technology and analyzed via LC-MS/MS on an Evosep One-timsTOF Pro2 platform. Differentially expressed proteins will be identified using a data-independent acquisition (DIA-PASEF) workflow and validated in a subset of 200 patients through targeted mass spectrometry.

Clinical, analytical, and microbiological data will be collected via the REDCap platform. Machine learning models (XGBoost, SHAP interpretability) will be used to generate a predictive risk model for complications, integrating proteomic and clinical data.

This study is expected to establish a new decision-support tool for early identification of high-risk FN patients, facilitating personalized antimicrobial strategies and improved prognosis.

02

Conditions studied

  • Febrile Neutropenia

Keywords

  • febrile neutropenia
  • hematologic malignancy
  • proteomics
  • sepsis
  • biomarkers
  • septic shock
  • mass spectrometry
03

In context

Febrile Neutropenia

147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.

This study's planned enrollment of 350 is above the median of 131 across 46 observational studies indexed under Febrile Neutropenia.

Browse Febrile Neutropenia studies →

Lead sponsor

Instituto de Investigación Biomédica de Salamanca is the lead sponsor of 20 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Oncohematologic Patients With Febrile Neutropenia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years).
  • Written provided by patient or legal representative.
  • Diagnosis of hematologic under induction chemotherapy, post- hematopoietic stem cell transplantation, or CAR-T therapy.
  • High-risk febrile neutropenia (ANC ≤ 100 cells/mm³, expected duration ≥ 7 days, or significant comorbidities).
  • Fever defined as oral temperature ≥38.3 °C once or ≥38.0 °C for ≥1 hour.
  • Hospitalized or requiring immediate admission at the time of FN diagnosis.

    ´- Initial uncomplicated clinical presentation, with no previous infection or colonization by multidrug-resistant bacteria.

  • Eligible for initial monotherapy with broad-spectrum empirical antibiotic.
  • Availability for serial plasma sampling and clinical follow-up.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years.
  • Low-risk FN according to MASCC/CISNE criteria.
  • Initial sample collected after antibiotic administration.
  • Decline or inability to provide .
  • Any condition preventing safe participation or reliable sample collection.
  • Fever induced by noninfectious causes (considered as adjustment factor, not exclusion).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • High-risk FN cohort

    Adult onco-hematologic inpatients meeting inclusion criteria; two plasma draws at fever onset and 48 h.

    Biological: Plasma and DNA sample collection for proteomic and genomic analysis

Interventions

  • BiologicalPlasma and DNA sample collection for proteomic and genomic analysis

    Collection of 10 mL of peripheral blood in EDTA tubes at fever onset (before antibiotic initiation) and 48 hours later for proteomic and genomic analysis. Samples are processed to obtain plasma and DNA, which will be used for mass spectrometry-based proteomics and potential metagenomic studies.

06

What researchers measure

Primary outcomes

  1. Identification of plasma host-microbial proteomic signatures (combitypes) associated with major complications in febrile neutropenia.

    Evaluation of proteomic profiles (human and microbial) associated with hemodynamic instability, sepsis, septic shock, or death.

    Time frame: Within 7 days from fever onset.

Secondary outcomes

  1. Dynamic changes in plasma proteome over 48 hours

    Assessment of longitudinal variations in host and microbial protein levels between baseline and 48 hours.

    Time frame: 0-48 hours

  2. Predictive performance of identified combitypes versus conventional biomarkers (CRP, PCT)

    Comparison of ROC-AUC for new proteomic models against current inflammatory markers.

    Time frame: Up to 7 days.

  3. Correlation between microbial proteomic profiles and microbiologically documented infections

    Association between detected microbial peptides and confirmed pathogens.

    Time frame: During hospitalization (up to 30 days).

  4. Development of a predictive model for complications

    A predictive risk model for complications will be developed using machine-learning algorithms (XGBoost) based on the integration of plasma proteomic data and relevant clinical parameters collected at fever onset and during follow-up. The model will be trained and internally validated within the full study cohort using cross-validation techniques to optimize predictive performance and minimize overfitting.

    Time frame: Study duration (36 months).

  5. Validation of selected protein biomarkers by targeted mass spectrometry

    Selected protein biomarkers previously identified through discovery-phase proteomic profiling will be validated using targeted LC-MS/MS mass spectrometry in plasma samples from 200 patients within the study cohort. This validation phase will assess the analytical performance (including reproducibility, accuracy, and sensitivity) of the selected biomarkers, as well as their clinical relevance in predicting complications such as hemodynamic instability, sepsis, septic shock, or death. This outcome cannot be divided into sepparate ones, as biomarker expression will be analyzed as a whole, given the fact that until the trial begins, the biomarkers associated with complications in oncohematologic patients with febrile neutropenia will be unkown. This outcome will determine the feasibility of implementing the identified biomarkers as prognostic tools in routine clinical practice for the early risk stratification of patients

    Time frame: By end of study (month 36).

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Following anonymization, individual participant-level data supporting the publications will be made available. These data include demographic and clinical variables collected in REDCap. A data dictionary, eCRF, and-when possible-analysis scripts (R/Python) and FAIR-compliant metadata will also be provided. Data will be hosted within the controlled infrastructure of the project (XNAT/Core-lab) and, for controlled dissemination, within the Zenodo community of IBSAL, with DOI assignment and regulated access, in accordance with the GDPR/LOPDGDD and the study protocol as approved by the Research Ethics Committee.

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: Data will be available starting 12 months after publication of the primary results and will remain accessible for at least 5 years thereafter.

Access criteria: Qualified researchers with a methodologically sound proposal may request access. Requests will be reviewed by the study's Data Committee/Steering Committee. Applications should be addressed to the Principal Investigator (Jesús Francisco Bermejo Martín). A Data Use Agreement (DUA) will be required, including commitments to non-reidentification, appropriate data security, and mandatory citation of both the source and dataset DOI. Applicants may also be required to share their analytical code and a publication plan prior to authorization.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

Of 21 observational studies under Febrile Neutropenia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 60. This study's planned 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Dec 11, 2025
StartActual
Jun 9, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jan 2029
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07277387
Lead sponsor
Instituto de Investigación Biomédica de Salamanca
Responsible party
Sponsor
First posted
Dec 11, 2025
Start date
Jun 9, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Jun 15, 2026

Study contacts

Jesús Francisco Bermejo Martín, MD PhD
Contact
jfbermejo@usal.es
+34923 29 45 41
Nadia García Mateo, PhD
Contact
nadiagarciamateo@ibsal.es
+34923 29 45 41
Jesús Francisco Bermejo Martín, MD PhD
principal investigator · Centro Asistencial Universitario de Salamanca (CAUSA)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion